The ratio of miR-21/miR-24 as a promising diagnostic and poor prognosis biomarker in colorectal cancer.
Optimal management of cancer treatment will be guided by sensitive and specific biomarkers. Searching for potential biomarkers is always a hot spot in cancer research, including colorectal cancer (CRC). MicroRNAs (miRNAs) have been recently proposed as biomarkers for cancers. Based on previous miRNA analysis in our hospital and data mining, we hypothesized that the ratio of miR-21/miR-24 (miR-21/24) may serve as plasma biomarkers in CRC patients. The plasma levels of miR-21 and miR-24 were analyzed from the 186 CRC patients before surgery and 97 healthy controls by qRT-PCR. Receiver operating characteristic (ROC) analysis was further used to evaluate the difference in diagnostic accuracy associated with the expression of miR-21, miR-24 and their ratio. Chi-square2-test or Fisher's exact test was performed to determine the relationship between the ratio of miR-21/24 and clinicopathological parameters. Kaplan-Meier and log-rank testing were performed to evaluate the effect of miR-21/24 ratio on the survival of colon cancer. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated by Cox regression models. ROC curves revealed that the diagnostic accuracy AUC (area under the curve) in CRC tissue of miR-24, miR-21, and the ratio of miR-21/24 were 0.8971, 0.9128 and 0.9875, respectively. Notably, the ratio of miR-21/24, with the best accuracy among these miRNAs, was significantly correlated with several important prognosis factors in CRC, such as tumor size, TNM stage, lymph metastasis and histologic differentiation (all p<0.05). By Kaplan-Meier survival analysis and Cox regression analysis, the ratio of miR-21/24 was shown to be a significant survival risk factor for CRC patients. We showed that the plasma ratio of miR-21/24 is a potentially powerful tool for detecting CRC and predicting prognosis.